BRI Biopharmaceutical Research Inc. is a subsidiary of Frontage Laboratories since December 2019, specialized in bioanalytical analysis, In-vitro/In-vivo DM/PK ,CMC and animal efficacy models in support of CTAs & IND enabling pre-clinical and clinical development in Canada, USA, Europe and Japan. Frontage Laboratories offers DMPK, safety and toxicology testing, bioanalytical testing, CMC, agrochemical services and early stage clinical services.